CSPCY News and Press, CSPC Pharmaceutical Group Ltd ADR

2024-07-12 08:41:47 ET More on CSPC Pharmaceutical, Moderna, etc. Moderna: Really Strong Competition Moment Of Truth Approaches For Moderna's RSV Vaccine Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Moderna, Mitsubi...

2024-01-29 09:00:03 ET More on Corbus Pharmaceuticals Corbus Pharma surges after early Phase 1 data for tumor candidate Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals Historical earnings data for Corbus Pharmaceuticals Financial information for...

2024-01-26 13:34:16 ET More on Corbus Pharmaceuticals Seeking Alpha’s Quant Rating on Corbus Pharmaceuticals Historical earnings data for Corbus Pharmaceuticals Financial information for Corbus Pharmaceuticals Read the full article on Seeking Alpha ...

Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refract...

Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire NEW YORK , April 26, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology comp...

2023-03-29 07:00:00 ET Summary News of marketing approval for China’s first mRNA vaccine falls flat with investors, who worry the drug is being rushed to market before Phase 3 trials are complete. As the pandemic abates, the market for the vaccine is shrinking rapidly. ...

2023-03-22 06:23:09 ET China's National Medical Products Administration (NMPA) approved CSPC Pharmaceutical's ( OTCPK:CSPCY ) ( OTCPK:CHJTF ) mRNA COVID vaccine SYS6006 for emergency use, marking the country's first domestically developed mRNA vaccine. CSPC said SYS6006...

Summary Jiangsu Hengrui Pharma out-licensed US rights for a novel small-molecule EZH2 inhibitor in a $706 million agreement with Connecticut's Treeline Biosciences. A CSPC Pharma subsidiary out-licensed ex-China rights for a Nectin-4 antibody drug conjugate to Boston’s Corbus Pha...

Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC) PR Newswire CRB-701 (SYS6002) is designed for improved therapeutic index and to act on a broad range of Nectin-4 expressing tumors ...

CSPC Pharma out-licensed global rights (ex-China) for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. Chengdu’s Kelun-Biotech out-licensed global rights to an ADC candidate aimed at solid tumors to MSD (Merck) in a deal worth up to $936...